Related Experiment Video

Updated: May 26, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity

S Parmar1, C Schumann, S Rüdiger

  • 1Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Helmholtzstrasse 20, Ulm, Germany.

The Pharmacogenomics Journal
|December 14, 2011
PubMed

Insights

Genetic variations in EGFR and PIK3CA may predict skin rash in cancer patients treated with epidermal growth factor receptor (EGFR) inhibitors. This finding could personalize cancer treatment and improve patient outcomes.

Area of Science:

  • Oncology
  • Pharmacogenetics
  • Molecular Biology

Background:

  • Epidermal growth factor receptor (EGFR) inhibitors are crucial cancer therapies.
  • Skin rash is a common and potentially severe side effect of EGFR inhibitor treatment.
  • Understanding the genetic basis of this side effect can aid in patient stratification and treatment management.

Purpose of the Study:

  • To investigate pharmacogenetic factors influencing skin rash development during EGFR inhibitor therapy.
  • To identify specific genetic polymorphisms and haplotypes associated with EGFR inhibitor-induced skin rash.
  • To explore the relationship between these genetic factors, skin rash, and overall survival in cancer patients.

Main Methods:

  • Prospective sampling of 109 cancer patients initiating EGFR inhibitor treatment.
  • Genotyping of functional EGFR polymorphisms and tagging variants in downstream signaling genes.
  • Statistical analysis to correlate genetic variations with the incidence of skin rash and overall survival.

Main Results:

  • Skin rash occurred in 76.1% of patients and was linked to shorter overall survival (P=0.005).
  • Specific EGFR polymorphisms (497G/A, P=0.008) and promoter haplotypes (EGFR-216G/T, -191C/A, P=0.029) were associated with skin rash.
  • A PIK3CA gene haplotype correlated with both skin rash (P=0.045) and overall survival (P=0.009).

Conclusions:

  • Genetic variations within the EGFR gene may predict the occurrence of skin rash.
  • Downstream signaling genes, such as PIK3CA, also play a role in EGFR inhibitor-related skin rash.
  • These pharmacogenetic findings suggest potential for personalized medicine approaches in EGFR inhibitor therapy.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...